Figure 1.

(a) Schematic of rodent data from LS174T human colon cancers (A, C, D) and CT26 rodent colon cancer (B). Treated animals received Bevacizumab at 10 mg/kg on days 0, 3 and 7. Data set A and B are longitudinally imaged and used as training in the PCA/LDA approach and the GLMNET approach. Data set C is a separate cohort of 20 tumors used for repeatability assessment. Data set D was used as test data acquired separately from the main cohort, and n = 11 out of the 18 animals (5 treated, 6 control) had whole tumor histological assessment of CD31 MVD at 24 hours after treatment. (b) Computational pipeline developed to generate parametric maps and extract features, PCA and develop the LDA model. Additional details on each of these steps is presented in supplementary methods. (c) Representative 3D maps of AUC. Note heterogeneous perfusion in baseline and longitudinally in treated/control groups.